Innostar succefully assisted Signet Therapeutics in the IND approval by U.S. FDA of the world's first targeted drug for the treatment of diffuse gastric cancer

In the morning of February 1st, "the first round signing and groundbreaking ceremony of major science & technology industrial and supporting projects in 2023" was held in Pudong New Area with the theme of "Taking the Lead, Fighting for Speed and Breaking New Ground".

Shenzhen InnoStar Biomedical Safety Evaluation and Research Institute Co., Ltd. has successfully received the good laboratory practice (GLP) certification for conducting non-clinical studies from the National Medical Products Administration and become the first GLP-certified CRO company in Shenzhen.

The American Association for Accreditation of Laboratory Animal Care (hereinafter referred to as "AAALAC") sent an email recently to confirm that the Shenzhen InnoStar Biomedical Safety Evaluation and Research Institute Co., Ltd.

After a series of detailed inspections and reviews, Shanghai InnoStar has passed the expert review of the College of American Pathologists (CAP) and is recognized again by the international "Gold Standard" with the excellent performance of "zero defects".